

1     **Researchers’ experiences of the design and conduct challenges associated**  
2     **with parallel-group cluster-randomised trials and views on a novel open-cohort**  
3   **design**

4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

Claire Surr<sup>1\*</sup><sup>¶</sup>, Laura Marsden<sup>2¶</sup>, Alys Griffiths<sup>3</sup>, Sharon Cox<sup>4</sup>, Jane Fossey<sup>5</sup>, Adam  
Martin<sup>6</sup>, A Toby Prevost<sup>7</sup>, Catherine Walshe<sup>8</sup> and Rebecca Walwyn<sup>2¶</sup>.

<sup>1</sup>Centre for Dementia Research, Leeds Beckett University, Leeds, UK

<sup>2</sup>Clinical Trials Research Unit, University of Leeds, Leeds, UK

<sup>3</sup>Institute of Population Health, University of Liverpool, Liverpool, UK

<sup>4</sup>Department of Behavioural Science and Health, UCL, London, UK

<sup>5</sup>Faculty of Health and Life Sciences, University of Exeter, UK

<sup>6</sup>Academic Unit of Health Economics, University of Leeds, Leeds, UK

<sup>7</sup>Nightingale-Saunders Clinical Trials & Epidemiology Unit, Kings College London,  
London, UK

<sup>8</sup>International Observatory on End of Life Care, Lancaster University, Lancaster, UK

\*Corresponding author

E-mail: [c.a.surr@leedsbeckett.ac.uk](mailto:c.a.surr@leedsbeckett.ac.uk) (CAS)

<sup>¶</sup>These authors contributed equally to this work

27

## 28 **Abstract**

29

30 **Background:** Two accepted designs exist for parallel-group cluster-randomised  
31 trials (CRTs). Closed-cohort designs follow the same individuals over time with a  
32 single recruitment period before randomisation, but face challenges in settings with  
33 high attrition. (Repeated) cross-sectional designs recruit at one or more timepoints  
34 before *and/or* after randomisation, collecting data from different individuals present in  
35 the cluster at these timepoints, but are unsuitable for assessment of individual  
36 change over time. An 'open-cohort' design allows individual follow-up with  
37 recruitment before and after cluster-randomisation, but little literature exists on  
38 acceptability to inform their use in CRTs.

39 **Aim:** To document the views and experiences of expert trialists to identify:

- 40 a) Design and conduct challenges with established parallel-group CRT designs,
- 41 b) Perceptions of potential benefits and barriers to implementation of open-  
42 cohort CRTs,
- 43 c) Methods for minimising, and investigating the impact of, bias in open-cohort  
44 CRTs.

45 **Methods:** Qualitative consultation via two expert workshops including trialists (n =  
46 24) who had worked on CRTs over a range of settings. Workshop transcripts were  
47 analysed using Descriptive Thematic Analysis utilising inductive and deductive  
48 coding.

49 **Results:** Two central organising concepts were developed. *Design and conduct*  
50 *challenges with established CRT designs* confirmed that current CRT designs are  
51 unable to deal with many of the complex research and intervention circumstances  
52 found in some trial settings (e.g. care homes). *Perceptions of potential benefits and*

53 *barriers of open cohort designs* included themes on: approaches to recruitment; data  
54 collection; analysis; minimising/investigating the impact of bias; and how open-cohort  
55 designs might address or present CRT design challenges. Open-cohort designs  
56 were felt to provide a solution for some of the challenges current CRT designs  
57 present in some settings.

58

59 **Conclusions:** Open-cohort CRT designs hold promise for addressing the challenges  
60 associated with standard CRT designs. Research is needed to provide clarity around  
61 definition and guidance on application.

62

63 Keywords: Cluster randomised trials, expert consultation workshops, parallel-group  
64 design, open cohort, dynamic cohort, methodology, health economic evaluation

65

## 66 **Introduction**

67

68 Cluster-randomised trials (CRTs) randomise groups of individuals (“clusters”) to  
69 different interventions or sequences of interventions within a trial, as opposed to  
70 individuals. They have become increasingly more common since their initial use in  
71 the 1980s(1), with their use increasing since the early 2000s when the first  
72 CONSORT extension to CRTs was published(2). CRTs are widely used in settings  
73 where interventions are delivered in an attempt to change the culture, environment  
74 or general practices and to reduce contamination between arms. This frequently  
75 occurs in schools, care homes and healthcare settings including both primary and  
76 secondary care(3, 4). CRTs are also a common choice for trials conducted in  
77 communities or villages in low- and middle-income countries(5), where cross-  
78 contamination between arms or logistical and administrative reasons mean a  
79 standard RCT design would be problematic(6).

80

81 Two widely accepted designs currently exist for parallel-group CRTs. Closed cohort  
82 (CC) designs follow the same individuals over time, with recruitment occurring just  
83 once prior to cluster-randomisation. (Repeated) cross-sectional (R-CS) designs allow  
84 for recruitment before and/or after cluster-randomisation at one or more discrete time  
85 points, collecting data from different individuals present in the cluster at these  
86 timepoints. Some individuals are potentially measured more than once(7) but  
87 repeated measurements on individuals are often not linked over time. Other designs  
88 exist, but they are currently not labelled and each requires their own methodological  
89 literature. The focus of this paper is on open cohort parallel-group CRTs.

90

91 CRTs with CC designs face challenges in settings with high attrition rates. Such  
92 settings include care home and palliative care settings, largely due to participant  
93 death or moving to another setting, as well as other settings such as prisons, where  
94 the presence of prisoners with shorter sentences similarly leads to high participant  
95 turnover. There are examples of CC CRTs in these settings where fewer than 50%  
96 of baseline participants were remaining at trial end, decreasing statistical power and  
97 potentially leading to attrition bias, consequently compromising internal and/or  
98 external validity(8-12).

99

100 To overcome expected high attrition rates, CRTs may intentionally avoid evaluation  
101 of long-term outcomes from the outset(13), for example by including alternative  
102 primary and secondary outcomes and selecting follow-up periods that minimise  
103 attrition. Care home and palliative care trials may also use minimum life expectancy  
104 as participant inclusion criteria(14-16). In these settings, trialists have noted the  
105 difficulty of choosing a suitable follow-up period, identifying a trade-off between the  
106 trial being long enough to implement the intervention and assess its sustainability,  
107 but short enough to minimise losses (9, 17, 18). Anticipated attrition may, therefore,  
108 force adaptation of the research question when using a CC design, narrowing the  
109 target population to which inferences can be made. This is a concern as the  
110 research question should drive the trial design rather than vice-versa. Similarly, the  
111 R-CS design, due to its cross-sectional nature, is able to provide cluster-level  
112 inference at specific time points. It is generally unsuitable where the research  
113 questions involve an assessment of individual change over time.

114

## 115 **Motivating example for this study**

116 To provide a clear rationale for the need to consider novel “open-cohort” trial designs  
117 we will present details of a motivating study, which exemplified how neither of the  
118 established designs were entirely suited to achieving the trial’s objectives. The  
119 issues presented in this motivating example are not exclusive to this trial, but  
120 common to other CRTs in settings where the intervention operates at a cluster level  
121 and requires a period of follow-up that is likely to mean high study attrition. However,  
122 such design challenges largely remain unacknowledged in trial reporting.

123

124 The DCM-EPIC trial(19), was a parallel-group CRT with economic evaluation where  
125 clusters (care homes) were randomised to a Dementia Care Mapping (DCM)  
126 intervention plus usual care, or usual care only. DCM involves observation of care  
127 practice using a standardised tool, analysis of data and feedback of findings to the  
128 staff team. These are then turned into action plans for care home and individual  
129 resident level practice change and comprise one practice development cycle. Thus,  
130 the intervention comprised both individual and cluster level components, which had  
131 an overall aim of improving care quality, with the ultimate aim of impacting resident  
132 outcomes. The primary continuous endpoint was resident-level agitation assessed  
133 16-months after cluster-randomisation. The 16-month timepoint was adopted since  
134 the intervention needs time to embed into practice, and this endpoint permitted 3  
135 ‘cycles’ of DCM. Data was also collected at 6-months post-randomisation.

136

137 Originally, DCM-EPIC had a CC design as individual change over time was of  
138 interest (Resident A, Fig 1). However, trial monitoring indicated that up to 50% of  
139 residents could be lost to follow-up by trial end (Resident B, Fig 1), predominantly

140 due to death, with a smaller number of residents moving out of the care home.  
141 Continuation with the CC design would have led to lower statistical power and  
142 questionable external validity, as the sample of residents remaining at 16-months  
143 would not have been representative of the general care home population. A design  
144 change was approved by the funder and ethics panel which included recruitment of  
145 additional residents at 16-months from randomisation of the cluster (Resident C, Fig  
146 1), and the primary endpoint instead utilised a cross-sectional analysis.(19)

147

148 **Fig 1. Illustration of four different scenarios for residents in DCM-EPIC care**  
149 **homes.** Black circles denote a resident's presence; white circles denote the time a  
150 resident moved, withdrew from the trial, or died. Resident D was not recruited into the  
151 trial. CR = cluster randomisation.

152

153 DCM-EPIC analysis and final trial reporting meant that although Resident D (Fig 1)  
154 was exposed to the cluster-level intervention, they were not recruited due to the  
155 timing and spacing of recruitment and measurement points. Thus, the number and  
156 timing of measurement and recruitment points is important in determining which  
157 residents are sampled. Given the original trial design an acceptable compromise for  
158 analysis and reporting was adopted (traditional R-CS analysis). However, neither the  
159 original CC design nor a R-CS approach made full use of the data collected from  
160 residents in DCM-EPIC, which had implications for statistical power, trial resource  
161 use, costs, and interpretation of results.

162

## 163 **A case for alternative trial designs**

164 Whilst reviews have highlighted parallel-group CRTs using *both* closed cohort and  
165 cross-sectional approaches within the same trial (20, 21), this was to address  
166 different endpoints as opposed to a single design which unites the two approaches.  
167 CC and R-CS designs appear to be viewed as the only two possible, mutually  
168 exclusive options for parallel-group CRTs, forcing trialists to choose between them.  
169 To overcome the aforementioned issues in future, an ideal design would collect both  
170 CC (A) and cross-sectional (C) data, as well as data from CC participants lost to  
171 follow-up (B) and from those present in between baseline and final follow-up (D), all  
172 contributing to assessment of the same endpoint. This design, which allows for  
173 recruitment of individuals both before and following cluster-randomisation, and  
174 repeated measurements on individuals that crucially can be linked over time (unlike  
175 repeated cross-sectional samples), could be described as an “open cohort” or  
176 “dynamic cohort” design. We will refer to it as open-cohort (OC). The OC design  
177 leads to missing baseline data by design for participants recruited after  
178 randomisation.

179

180 However, there is little methodological literature published to inform OC designs for  
181 CRTs(22) or experience to suggest their acceptability as a valid trial design by  
182 trialists. Therefore, to further the utility of OC designs, this study is part of a larger  
183 MRC-funded study on ‘OPen-cohorts in Institutional Settings: designs for Cluster-  
184 Randomised Trials’ (OPIS-CRTs), which includes a literature review, user  
185 engagement, statistical development and evaluation, and practical guidance which  
186 aims to address these gaps. This paper reports on the user engagement component.

187



## 188 **Objectives**

189  
190 To document the views and experiences of expert trialists involved in parallel-group  
191 CRTs to identify:

- 192 1. Design and conduct challenges with established parallel-group CRT designs,
- 193 2. Perceptions of potential benefits and barriers to implementation of OC  
194 parallel-group CRTs,
- 195 3. Methods for minimising, and investigating the impact of, bias in OC parallel-  
196 group CRTs.

197

## 198 **Design and methods**

199

200 This study adopted a qualitative expert consultation approach, through conduct of  
201 expert workshops.

## 202 **Expert workshops**

203 Expert workshops are facilitated small group events that allow individuals with  
204 experience in the domain of focus, to actively participate in discussion and activities  
205 to achieve a particular outcome.(23) They provide an opportunity to gain immediate  
206 reaction to, and feedback on, presented information through a semi-structured  
207 approach to facilitating discussion, while permitting flexibility to respond to and  
208 explore issues that emerge during discussions.(24)

209

210 Two workshops were held in 2019, the first with expert trialists who had worked on  
211 the DCM-EPIC CRT(25) (many of whom had also worked on other CRTs) and those  
212 who had recently conducted CRTs in care homes or hospices. The second included

213 a broader group of expert trialists with experience of CRTs, with diverse professional  
214 backgrounds, working across a range of fields and service settings, none of whom  
215 had worked on DCM-EPIC.

216

## 217 **Recruitment and consent**

218 Purposive and snowball sampling were used to identify workshop participants with  
219 relevant expertise, representative across a range of trial roles (e.g. chief investigator,  
220 statistician, health economist, academic or clinical researcher). Potential participants  
221 were identified through the research team's existing networks, approaching  
222 corresponding authors on relevant published studies identified in the literature review  
223 component of the larger study and by contacting Chief Investigators on current or  
224 recently completed, relevant trials listed on trial registers and databases of National  
225 Institute for Health and Care Research funded studies. Recruited participants were  
226 asked to suggest other individuals to approach, whose expertise would address any  
227 sampling gaps.

228

229 Inclusion criteria were:

- 230 1) Has taken part in a CRT (for Workshop 1 only, conducted in care homes or  
231 hospices).
- 232 2) Has an in-depth understanding of trial design and methods.

233

234 Participants were approached by e-mail by a member of the research team. They  
235 provided written informed consent to participate and were reimbursed for their travel  
236 but were not paid for attending.

237

## 238 **Data collection**

239 The expert workshops took place on 1<sup>st</sup> May and 16<sup>th</sup> October 2019 respectively and  
240 were held face-to-face with the option to join by video conference where necessary.

241 They were audio recorded and transcribed with 2-months of the workshop. Both  
242 workshops took place over a full day.

243

244 Each workshop was facilitated by five members of the study team [redacted] and  
245 consisted of short presentations on topics associated with the design and conduct of  
246 CRTs, including those with OC designs, followed by guided discussion. Topics  
247 included i) recruitment, bias and data collection, ii) the impact of intervention type  
248 and iii) intervention dose and exposure time. Workshop 1 focussed on CRT design  
249 and conduct where clusters are care homes or hospices; both workshops explored  
250 the use of OC designs as a potential alternative to established CC or R-CS designs.

251 A list of potential challenges and solutions was generated. Those identified in  
252 Workshop 1 were synthesised by the research team and taken forward to  
253 discussions in Workshop 2.

254

## 255 **Ethical issues**

256

257 Leeds Beckett University ethical approval was obtained for the study. All participants  
258 provided written informed consent to participate. While confidentiality of individuals  
259 was maintained in analysis and presentation of the data, all workshop participants

260 were given the opportunity to co-author this paper (subject to meeting co-authorship  
 261 requirements) or to be named in the acknowledgements.

## 262 **Data analysis**

263 Data were analysed during April and May 2021, using Descriptive Thematic  
 264 Analysis(26) using both inductive and deductive coding. An initial set of deductive  
 265 codes were developed based on the study objectives above (challenges, barriers  
 266 and facilitators of different CRT designs). Inductive codes were developed  
 267 associated with these deductive codes and where other topics of importance were  
 268 identified in the data. Once coding was complete, codes were refined to form the  
 269 themes and sub-themes presented. Coding and theme development was conducted  
 270 by the first author and all transcripts and all coded data was reviewed by the second  
 271 author to check meaning and corroborate themes. Disagreements were identified  
 272 and discussed to reach agreement and refine themes accordingly.

273

## 274 **Findings**

### 275 **Participants**

276 Nine expert trialists participated in Workshop 1 (W1) and 15 in Workshop 2 (W2).  
 277 Their demographics are presented in Table 1.

278

279 Table 1: Demographics of expert workshop participants

	Workshop 1 n=9	Workshop 2 n=15	Total N=24
<b>Sex, n</b>			

Female	6	10	16
<b>Professional role(s)*, n</b>			
Statistician	2	10	12
Health Economist	2	1	3
Clinician	2	1	3
Academic subject expert	2	1	3
Trialist/ Methodologist	1	2	3
Funding panel member	-	2	2
<b>Previously worked on DCM-EPIC CRT?</b>			
Yes	5	0	5

280 \*Participants may fulfil more than one professional role

281

282 Two central organising concepts, four themes and four sub-themes (associated with  
283 two themes) were identified in the data (see Fig 2).

284

285 **Fig 2. Organising concepts, themes and sub-themes**

286

## 287 **Design and conduct challenges with established parallel-** 288 **group CRT designs**

289 Participants of both workshops identified a need to consider alternatives to CC and  
290 R-CS parallel-group CRT designs due to common challenges experienced. High loss  
291 to follow up was identified as being the greatest challenge faced. In care home and  
292 palliative care settings, high loss to follow up due to death or transfer out of the  
293 setting was expected and unavoidable:

294

295 P8: So we're not looking at these [high loss to follow up rates] being unusual  
296 and...as the criteria get higher...to be admitted into residential care or nursing  
297 care...you're going to see people with much higher levels of frailty and other  
298 co-morbidities that...mean people are going to have less average time in a  
299 care home. W1

300

301 P7: So of all of the trials [in a systematic review] that reported readings for  
302 their losses, 60% of them were due to death. So it's unavoidable...

303

W1

304

305 P6: ...if you want to understand how an intervention works in practice I can't  
306 really see a reason – I'm exaggerating slightly – to have a closed cohort,  
307 because that's not what nursing homes are. So that's not real life, that's not  
308 pragmatic...we know in any 12-month period, 30-40% of residents will change  
309 and often that is because of death...so I would really struggle with a...care  
310 home trial that explicitly excluded people who they expected to die...

311

W1

312

313 Use of a CC design, where the cluster is inherently not closed, and in the face of  
314 high loss to follow-up, could result in missing data, loss of study power, problematic  
315 variation in cluster sizes and loss of entire clusters, introducing bias and raising  
316 issues for generalisability. If a R-CS design was adopted to address this, recruitment  
317 bias could potentially be introduced. Some participants may then be present in the

318 dataset at more than one timepoint, without this being considered or accounted for  
319 within the analysis.

320

321 P5: In [trial name], I think the minimum was six [participants per cluster], to  
322 make the cluster viable... and other in homes sometimes, 40 people [in the  
323 cluster] how are you generalising data across them? W2

324

325 P1: at the moment we're excluding the people who die pretty quickly and...so  
326 we're only able to generalise [study findings] to the people who don't die  
327 particularly quickly.

328

329 P10: I suppose it depends whether your intervention is trying to target both  
330 groups and you might have different interventions that would work improving  
331 the quality of life for people who are expected to die quite quickly...But would  
332 those interventions also benefit the ones who are staying in the care home  
333 longer? W1

334

335 A number of workshop participants reported using recruitment post-randomisation to  
336 address high loss to follow up in their CRTs, with some not modifying their analysis  
337 approach, or needing to conduct more than one analysis.

338

339 P9: There's the [Name] trial that we worked on...and it was the same thing,  
340 recruiting additional participants prior to the primary outcome at 12-months  
341 due to the drop out levels...I don't think it changed the analysis. W1

342

343 P13: ...a trial in nursing homes...we did have this problem about continuing to  
344 recruit participants if they were eligible during the trial because we wanted to  
345 increase our power and we ended up doing two types of analysis. One we  
346 called the cohort analysis which was the people that started at the beginning  
347 and then one we called the cross-sectional study which was just people that  
348 were [recruited post-randomisation] at 12-months. W1

349 Thus, participants identified a need for alternative trial designs and appropriate,  
350 associated analysis methods.

351

352 Managing high loss to follow-up by limiting the follow-up period was identified as  
353 potentially appropriate for some interventions targeted at individuals in certain  
354 settings (i.e. palliative care) but may not be appropriate for other interventions and  
355 other settings. Short follow up raised problems for interventions, potentially at the  
356 cluster level, that need time to embed, or for effects to be realised, and meant  
357 sustainability could not be monitored.

358

359 P6: ...if it's a palliative or end of life care intervention in a care home...you  
360 would be expecting people to die, so...we have a short follow up to try and  
361 capture as many people as possible,...and...there would be an assumption –  
362 dose is really an important issue....if it doesn't work rapidly it's not worth  
363 doing. W1

364

365 Modifying standard trial designs to accommodate likely high loss to follow up, by  
366 adding or imposing strict eligibility criteria for example, was seen as sub-optimal.



367

## 368 **Perceptions of potential benefits and barriers of OC**

### 369 **parallel-group CRTs**

370 Workshop participants perceived that an OC design might provide a more efficient  
371 trial design, although this might not necessarily be the case if more complex  
372 analyses were planned. Designing a CRT as open-cohort from the outset was felt  
373 important to supporting appropriate decision-making and consideration of the range  
374 of design, implementation and analysis issues OC designs still raised.

375

376 P15: But I think from a design point of view to say that you were going to do  
377 this from the start ... there were good reasons for doing it – so I think to set it  
378 up from the start is then a lot clearer about what people's expectations are.

379

W1

380

381 Only interventions that were truly cluster targeted were felt to be appropriate for an  
382 OC design.

383

384 P6: I think it really depends on the type of intervention and whether [there is]  
385 exposure to everybody ... within the care home or whether some are ... only  
386 delivered to some people ... but the reason for choosing a cluster design is  
387 because you expect some leaking of the intervention out to everybody else.

388

W1

389

390 A range of design, conduct and analysis issues important for OC designs were  
391 identified as sub-themes (see Fig 2).

392

### 393 **Recruitment – discrete or continuous?**

394 To address high loss to follow up, there was a strong consensus that either  
395 recruitment at one or more set time-points post-randomisation (discrete), or ongoing  
396 screening and recruitment at point of entry into the cluster (continuous) were  
397 particularly desirable aspects of an OC CRT design, due to the subsequent ability to  
398 recruit a more representative sample and improve generalisability. However,  
399 workshop participants highlighted practical challenges that recruitment post-  
400 randomisation (discrete or continuous) might present, with burden identified as the  
401 biggest challenge. This was particularly identified in sites which are less research  
402 ready/active, such as care homes, which generally then require considerable  
403 researcher resource to support recruitment.

404

405 P4: I think it also depends on whose burden it is... if we could have  
406 researchers going in and doing the majority of the research activity that's  
407 researcher burden...if you could minimally involve staff then it's potentially  
408 feasible to recruit W1

409

410 P3: The study we've just finished it takes something like two and a half hours  
411 to drive from the most northerly care homes to the most southerly care homes  
412 so doing it in a day – no. W1

413

414 Turnover within the trial setting impacting availability of trained staff to support  
415 ongoing screening and recruitment was also a potential barrier to continuous  
416 recruitment. This might be a particular challenge in sites with high staff turnover and  
417 few staff who have the expertise to support research activities, such as care homes,  
418 hospices, or other community settings.

419

420 P1: How are you going to manage the continual recruitment if you've ...to go  
421 back in hoping there's going to be enough staff trained to keep that  
422 recruitment going? W2

423

424 Participants in Workshop 1 agreed that, despite the potential benefits, continuous  
425 recruitment was unlikely to be desirable or practical in care homes or other similar  
426 settings, where research trained staff with resources to support research (for  
427 example NHS Research Nurses) were not available. Thus, recruitment at discrete  
428 timepoints probably provided the most appropriate option.

429

430 P7: I think in summary we're kind of saying we'd kind of like to do continual  
431 recruitment and data collection but it's probably not very practical.

432

433 P8: And I think not continuous but maybe at frequent timepoints and that  
434 would have to be decided based on the intervention and how long you need to  
435 follow up to be

436

437 P3: studies within the NHS ... there might be research nurses on site every  
438 day...to recruit participants to a study, [you] have to recognise that [a

439 researcher is] only going to be there intermittently [in a care home] so...unless  
440 the recruitment is actually being done by the people who are employed within  
441 the care home, ... it's never going to be continuous, there is always going to  
442 be some intermittent nature to it. W1

443

#### 444 **Data collection – managing post-randomisation recruitment.**

445 The challenges identified with recruitment also applied to data collection. Discrete or  
446 continuous recruitment post-randomisation raised practical challenges for when and  
447 how it was appropriate to collect baseline and follow-up data.

448

449 Discrete or continuous recruitment post-randomisation raised practical challenges for  
450 identifying an appropriate baseline timepoint for each trial participant. For example, if  
451 baseline was the day of entry to the cluster, data covering the period prior to this was  
452 then not available, which might be necessary for a health economic analysis.

453

454 P6: often the primary analysis for health economics is cost utility [i.e. Quality  
455 Adjusted Life Years measurement], and that...requires collection of the array  
456 of costs...over time rather than a snapshot. W1

457

458 However, setting the baseline after a period of being present in the cluster might  
459 potentially expose a participant to the intervention prior to their baseline data  
460 collection. This also applied to instances of changed eligibility, for example, where a  
461 resident was ineligible at cluster randomisation but later became eligible.

462

463 P6: if you only want to collect data from people with advanced dementia,  
464 some of them may be present in the home when you start the study but will  
465 actually only become eligible...at some point during the study.

466

467 P8: Yeah, that's another point. You could be exposed to the intervention  
468 before you're actually eligible for the trial. W1

469

470 Following identification of an appropriate baseline, similar burden challenges as  
471 those for continuous recruitment were noted for continuous measurement, with some  
472 solutions offered such as reducing the number of outcomes collected or using  
473 routinely available data.

474

475 P7: So you might perhaps reduce down the number of outcomes that you  
476 actually collect in order to make that more feasible W1

477

478 P4: but then...the collection of continuous data I think becomes  
479 unmanageable...you're...going to need some staff involvement for proxy data.  
480 So it just becomes too excessive. Discrete timepoints is a good thing but  
481 perhaps slightly more frequently...it's a fine balance between collecting the  
482 data and creating too much burden. W1

483

484 P5: ...if there was some routine data that...could be standardised, collected in  
485 all care homes it wouldn't create additional burden. W1

486

487 Workshop participants identified that the feasibility of continuous measurement might  
488 also depend on the nature of the outcomes being measured. They agreed that  
489 continuous recruitment did not have to necessitate continuous measurement; and  
490 measurement could instead be undertaken at discrete intervals. Continuous  
491 measurement might offer benefits for particular analysis approaches, but would  
492 potentially limit which outcomes could be assessed, especially when this data needs  
493 to be collected directly from participants or proxies.

494

495 P6: why would you necessarily have to do measurement at fixed times?

496 Because in individually randomised trials, it's always sort of [a] floating time  
497 zero that's relevant to that individual isn't it?

498

499 P1: Fixed for individuals, but then obviously, that's a massive resource...

500 Because you'd have to be back in each individual care home

501

502 P6: So, it depends on the outcome, how they are collected. W2

503

504 P5: I mean I'm struggling to work out how you would ever have continuous

505 data collection other than retrospectively going back to look for events

506 because you wouldn't be collecting quality of life or patient reported outcomes

507 continuously. They're always going to be at...discrete intervals. W1

508

509 **Data Analysis – a complexity of factors**

510

511 Participants identified a complexity of factors that must be considered when  
512 analysing CRT data with post-randomisation recruitment, thus highlighting potential  
513 challenges for OC designs. These included the handling of missing data and the  
514 exposure, duration and dose of intervention.

515  
516 Discussions included whether death of a participant reflected missing data or should  
517 be considered an outcome, with different interpretations of this between the  
518 statistical and health economic analyses. Whether mortality was an outcome the  
519 intervention was expected to impact was identified as an important consideration, as  
520 this would influence how data missing due to death is treated.

521  
522 P2: I feel that inevitably death is an outcome and I'm nervous of disregarding  
523 that outcome and I guess it's a research question. If death is something that  
524 you try to avoid ...[as] part of the research question then clearly, whether  
525 somebody dies or not is an outcome.

526  
527 P12: In health economics I don't think we'd say that death was missing data.  
528 For QALYS it obviously is zero, that's not missing... W1

529  
530 P3: To me, if you're interested in people's duration of time in the care home  
531 [vs when not in the care home] then you're not going to be imputing any of  
532 their data.... including the people who have died. W1

533  
534 Participants felt that statistical analysis methods needed to consider a range of  
535 factors: the specific estimand (e.g. intention to treat (ITT), per protocol, or something

536 else entirely); the proposed intervention effect(s) (e.g. whether death or moving out  
537 of the cluster were potential outcomes); whether follow-up beyond a person's stay in  
538 the cluster was desirable (e.g. if outcomes are relevant to follow up if the participant  
539 moves care home) if feasible; how missing data was handled; and when imputation  
540 was appropriate. Thus, such decisions would need to be made on a trial-by-trial  
541 basis.

542

543 P7: I think it depends on what is the estimand you're trying to capture. So if  
544 we are interested in an intention to treat estimand I would say yes. You have  
545 to go and follow them...if they left the nursing home....Now it's a different  
546 matter if they die because I only use data that still exists...as opposed to  
547 counterfactual data....So I never impute dead people but I impute people that  
548 have been lost to follow on. And if I'm...only interested in people that remain  
549 exposed to the randomised treatment and that's a different matter.

550

W1

551

552 P3: ...in our particular case if the intervention...[meant they were] less  
553 agitated then...there would be less care need for that person. So it may be  
554 informative the fact that they are having to move into a new care home....also  
555 ...going to a new care home is a way of rescuing them from the current  
556 environment that they're in and putting them into one that's more appropriate  
557 for their needs.

558

559 P7: I agree but so long as you did this then you're no longer doing an intention  
560 to treat [analysis] and you've started to do a different type of analysis.



561

562 P3: And therefore you have a question as to whether your primary analysis  
563 should be the ITT one or not. W1

564

565 Considerations for missing data were identified, such as whether it would logistically  
566 be possible to follow up those who left a cluster, or whether more realistically this  
567 data would need to be imputed. Reasons for leaving the cluster were felt to be  
568 important for the imputation model, but there were disagreements about what these  
569 might be.

570

571 P7: As long as they're alive, yes I would try to impute them.

572

573 P5: But what we require then is reasons why they've left their care homes so  
574 we can use that in information in the imputation process.

575

576 P7: ...I would ... construct an imputation model that tries to reconstruct the  
577 conditional distribution of the outcome given all their characteristics ...then as  
578 secondary analysis we could do something statistically where we think that  
579 perhaps those people that moved out, moved out for a reason and maybe  
580 they're different from the ones that are staying ... assuming that they're the  
581 same... is for me like a first safe bet.

582

583 P5: Do we really believe that's a safe bet though because the people who are  
584 missing – and there's a sizeable proportion of them – are really the same as  
585 those that aren't missing?

586

587 P3: ...potentially – If you were to say that they were more close to the type of  
588 care home that they went into then that potentially would be one way of  
589 dealing with it and I'd be much happier.

590

591 P7: Yeah, correct...Why I'm saying it's the safe bet is because the rest are just  
592 even stronger assumptions. I'm with you that probably they're different but we  
593 don't really know how different they are W1

594

595

596 Discrete and continuous recruitment post-randomisation also raised challenges for  
597 intervention type, exposure, duration and dose. Intervention type was identified as  
598 influencing exposure and dose and thus the appropriateness of an OC design.  
599 Understanding potential dose-response relationships was felt an important  
600 consideration, particularly when participants might receive variable exposure to the  
601 intervention dependent on point of entry to, or exit from, the study.

602

603 P4: I think for the sort of studies we do,...dose is really challenging and that's  
604 what we struggle with...It's like a pharmaceutical study where we say 'do you  
605 know what? I've no idea whether you need 100 milligrams or 1000 milligrams.  
606 They've got the precursor studies so they know what the safe dose is – we  
607 don't tend to do that.

608

609 P6: It's a sort of logic model idea isn't it? Saying how much we think. You'd  
610 have to make a rational case for how much the dose you think may be  
611 effective and may have a physiological or psychological, social effect.

612 W1

613

614 Workshop participants discussed how variable exposure might result from  
615 intervention sustainability or decay effects, the point of joining the cluster and the  
616 length of time in the cluster. This could be further complicated by whether a dose-  
617 response relationship is anticipated, learning curve and implementation delay  
618 effects, or intervention decay. All of these were felt to require consideration as part of  
619 the statistical analysis.

620

621 P2: And [it] depends on if there's a dose-response relationship...whether the  
622 intervention is expected to have the same effect over a 3-month period as it  
623 would over a 6-month period or whether a 6-month period would be doubly  
624 effective

625

626 P1: But if the intervention effect isn't sustained, if there's a waning....

627

628 P3: I guess this is also an outcome issue but ...if you're collecting baseline of  
629 someone who joins the home at 6-months, the intervention's already  
630 established... W1

631

632 P2: ... for very onerous interventions that require staff to do lots of things well  
633 after the first initial period. If it is the same staff maybe they stop following

634 guidelines? So maybe those individuals that are recruited to the trial much  
635 later get less exposed .... W1

636

637 Variable exposure was acknowledged as potentially further complicated by a  
638 clustering effect of the intervention.

639

640 P1: And that average dose [assumed in statistical analysis] might be different  
641 in different clusters. So it might be tied up in the clustering effect as well. So  
642 how do you disentangle that? W1

643

644 Looking beyond the challenges, workshop participants felt that an OC design  
645 required analyses to consider differing lengths of stay and to potentially link this to  
646 intervention effect, which was often not considered in other CRT designs.

647

648 P5: ...is it interesting to look at dose and time. We don't tend to look at that  
649 much individually in randomised trials do we? We just always stick with the  
650 ITT analysis and if we do look at dose it's always gonna be a supplementary  
651 thing that's not that interesting.

652

653 P1: You see I think the clinicians are interested in that and when you fail to  
654 detect an intervention effect on your ITT analysis they want to know more  
655 about why did it work for some people, did we give enough of the dose? ...

656

657 P3: Also I think it's that person's contribution to the treatment effect. I don't  
658 think it's fair that somebody's contributing the same amount to the treatment

659 effect if they're in the care home for a month as if they're in the care home for  
660 twelve months. W1

661

662 Yet, one workshop participant stated that even if an OC analysis was done, a more  
663 traditional analysis (i.e. CC or R-CS) should also be reported. This indicates a  
664 reticence, even among experts most likely to use OC designs, to move away from  
665 the more traditional analyses.

666

667 P13. ...one thing I would like to see is the traditional closed cohort presented  
668 either alongside or in a supplementary file...so what is the intervention now  
669 that we have this open cohort? It will have less exposure...I would worry that  
670 we're analysing some average exposure which is very difficult to generalise to  
671 the general population unless you're telling us exactly what you mean by  
672 exposure – maximum exposure. The closed cohort I understand...because  
673 you know, for the duration of the cohort they were exposed to whatever...so  
674 maybe as an insurance policy I would like to see the more traditional analysis  
675 as well. W1

676

677 Even so, workshop participants commented that OC designs could create options for  
678 statistical analyses that specifically handle variable intervention exposure and time in  
679 the cluster.

680

681 P5: Is there a different challenge for the economic analysis that you're not  
682 observing people over the same length of time?

683

684 P6: It depends, if you expect there's an impact on survival you think.

685

686 P2: And depends on if there's a dose-response relationship...

687

688 P3: I think that's an issue for the statistics as much as it is the health  
689 economics.

690

691 P3: ...actually I agree that that's not ideal but if you were to do an open cohort  
692 analysis you would allow for the fact that the people who have been in the  
693 care home over a period of time... W1

694

695

## 696 **Methods for minimising, and investigating the impact of, bias**

697

698 Workshop participants recognised that, due to the inability to not inform staff and  
699 residents of their intervention allocation, recruitment following randomisation  
700 included a risk of recruitment bias. This has the theoretical potential to impact  
701 willingness to consent, and lead to changes in staff and resident demographics. One  
702 participant (W1 P4) described this as becoming a 'magnet home', where certain staff  
703 or residents might choose to work/live, or which might alter the type of residents a  
704 care home felt able to admit/provide care for.

705

706 P15: ...I think there are some issues there then about people's willingness to  
707 participate depending on how they've been randomised in the first place.

708

W1

709

710 P5: depending on how long the recruitment is,...if your intervention is working,  
711 ... indicators for that care home go up, then people will want to come to it, and  
712 you'll then have different people. W2

713

714 P1: If the...[care home] staff are better able to deliver care to more complex  
715 residents...it can...end up with people [moving in] who are more complex to  
716 start with...So, you've actually nullified any impact of the intervention...

717

W2

718

719 The potential for recruitment bias and differences in average time in the cluster  
720 between arms was noted as a problem with R-CS designs as well.

721

722 P2: I don't see why they aren't saying exactly the same about cross-sectional  
723 studies. Why are we able to publish those when we can't even look into those  
724 at this particular level of detail,...with this [open cohort design], at least we  
725 have some way of knowing the pattern of people who were recruited before  
726 randomisation versus the people who were recruited afterwards, which to me,  
727 makes it less worrying. W2

728

729 Workshop participants identified potential solutions to address recruitment bias  
730 including having tight inclusion and exclusion criteria, recruiting everyone eligible  
731 wherever possible, monitoring expected flow of participants into the cluster, and  
732 using blinded recruiters. Alternatively, using anonymised routine data that do not  
733 require individual consent was identified as a solution.

734

735 P10: I think you'd have to have an absolutely rock solid, objective entry  
736 criteria for the study wouldn't you?...I suppose the other way would be  
737 ...somehow just use your routine data so that you didn't have to get...  
738 individual consent W1

739

740 P9: So, we've done a kind of, open cohort...in emergency settings. And,  
741 we've been able to have a good control in estimating the numbers of people  
742 coming through and hence knowing that we've always got the right proportion  
743 [consenting per arm], that the characteristics of the proportions remains  
744 similar over time...

745

746 P3: One of the ways of preventing it, is just to recruit everybody at the  
747 cluster... W2

748

## 749 Discussion

750

751 This study is the first to consider, with expert trialists, the challenges of conducting  
752 parallel-group CRTs in institutional settings and their perspectives on a novel OC  
753 CRT design as an alternative. Workshop participants identified challenges  
754 associated with conducting parallel-group CRTs using established designs, with the  
755 predominant problem being expected large loss to follow up in some settings such  
756 as care homes and hospices. This reflected our experiences in the motivating case  
757 for this study, the DCM-EPIC CRT. Participants could generally recognise the value  
758 of OC designs but posed several questions around if and when an OC design might  
759 be appropriate.



760

761 While one of the primary features of OC CRTs, recruitment post-randomisation, was  
762 felt to be a key strength of the design, practical, methodological and statistical issues  
763 related to the feasibility of continuous recruitment were identified. Discrete  
764 recruitment points post-randomisation were felt to offer a solution to practical  
765 challenges associated with the resource intensive nature of recruitment, although  
766 palliative care trials have found resources and workload associated with this present  
767 a challenge for recruitment over longer periods.(27) In this study participants felt  
768 issues of potential sample bias and differential exposure to the intervention were less  
769 easily solved. While studies have considered ways in which allocation techniques  
770 can help to address balance at baseline in CRTs(28), there is less evidence related  
771 to this for recruitment post-randomisation. Use of masked or independent recruiters,  
772 (29, 30) and objective eligibility criteria(31) have been suggested as methods to limit  
773 the risk of recruitment bias, and baseline testing(32) and reporting of appropriate  
774 information(33) as methods for measuring it, however, further research that can  
775 address this gap is required.

776

777 Associated with recruitment post-randomisation was the related challenges for data  
778 collection including identification of baseline, timing of follow-up and implications for  
779 resources. Participants identified that routine data might address some, but not all, of  
780 these challenges. Routine or minimum datasets are readily available in some  
781 countries and settings, although concerns have been raised about the quality,  
782 completeness(34), comparability(35) and scope(36, 37) of data available for  
783 addressing research questions. However, in others for example UK care homes,  
784 there is no standardised method for capture of such data(38) and existing datasets

785 may be fragmented.(39) Data linkage between social care and health data sets can  
786 be challenging and require specialist skill and resource.(40, 41) Thus, use of routine  
787 data may be realistic currently only for some outcomes, but holds future promise.

788

789 There were significant differences of opinion of workshop participants around  
790 approaches to statistical and health economic analysis and handling of missing data  
791 that require further exploration, to provide clearer guidance to statisticians and health  
792 economists around estimands, analysis methods and the assumptions underpinning  
793 these. Previous studies have identified challenges in incorporating cross-sectional  
794 data into health economic analyses.(42) Finally, learning curves and decay effects of  
795 the intervention and considerations of intervention sustainability identified in all CRTs  
796 remain challenges an OC design would need to address; this is likely to depend on  
797 the type of intervention and the level at which it is delivered. CRT analyses are often  
798 too simplistic, with intervention effects assumed constant following their  
799 implementation.(43, 44) Whilst tools already exist to encourage trialists to report  
800 details of how intervention drift was mitigated (e.g. Template for intervention  
801 description and replication (TIDieR)),(45) there is still a lot more to learn regarding  
802 intervention dose,(46) and more focused research in this area is required in general  
803 for CRTs evaluating complex interventions. Questions also remain around how to  
804 determine the sample size for an OC design. Whilst Kasza (22) recently provided the  
805 first framework for this, including design effects, sample size formulae for specific  
806 sampling schemes and an R Shiny app for users, only three sampling schemes were  
807 proposed and are therefore not likely to be sufficient for all types of open cohort  
808 design. Further work is therefore required in this area for these designs to be readily  
809 adopted by trialists.

810

## 811 **Limitations**

812

813 This is the first study to explore this topic with expert trialists. One limitation is that all  
814 trialists were UK-based and so the study does not include an international  
815 perspective. While workshop participants did represent the full range of trialist roles,  
816 it was weighted towards statisticians and to those working predominantly in care  
817 home trials.

818

819 Future work should include a literature review to assess the use of open-cohort  
820 designs within CRTs to date including how trial design might be influenced by the  
821 intervention, outcome type and setting. Clearer definition of OC CRTs as a study  
822 design is required, including guidance on when such designs are appropriate. It may  
823 be that in some situations, for example, more frequent measurement and an R-CS  
824 design is sufficient. Statistical development and evaluation should also be carried out  
825 to provide clear guidance on analysis approaches in OC CRT studies. This may  
826 include when it might be appropriate to exclude individuals from the analysis due to  
827 their limited exposure to the intervention.

## 828 **Considerations for researchers, funders and journal**

### 829 **editors**

830 Considerations for researchers, research funders and journal editors and reviewers

831

832 Researchers should:

- 833 - Openly acknowledge and critically address the challenges with conducting  
834 parallel group CRTs in populations or settings with unavoidably high attrition  
835 in grant applications and reporting of CRTs
- 836 - Propose appropriate, potentially non-traditional trial designs and analysis  
837 methods for trials in such settings
- 838 - Conduct methodological research to inform the development of guidance on  
839 OC and other potential non-traditional CRT designs

840 Research funders should:

- 841 - Actively encourage researchers to acknowledge the methodological  
842 challenges associated with conducting CRTs in settings with unavoidable high  
843 attrition
- 844 - Be open to considering grant applications that adopt alternative trial designs,  
845 such as OC, to meet these challenges, including reasonable requests for  
846 additional resources that such designs may require
- 847 - Fund methodological research into alternative trial designs

848

849 Journal editors and reviewers should:

- 850 - Actively encourage the open reporting of methodological challenges to  
851 conducting CRTs in settings with unavoidably high attrition, and the  
852 successes and challenges associated with approaches adopted to address  
853 these
- 854 - Publish studies that adopt non-traditional trial designs where they meet  
855 required markers of quality
- 856 - Publish research that advances methodological knowledge on OC and other  
857 non-traditional trial designs.

858

## 859 **Conclusions**

860

861 OC CRT designs hold promise for addressing some of the challenges associated  
862 with standard CRT designs. However, there currently remains limited research on  
863 such designs to provide clarity around definition and guidance on their application.

864

## 865 **List of abbreviations**

866

867 CC - Closed cohort

868 CRT - Cluster randomised trial

869 DCM - Dementia Care Mapping

870 ITT - Intention to treat

871 OC - Open cohort

872 RCT - Randomised controlled trial

873 R-CS - Repeated cross-sectional

874

875

## 876 **Declarations**

877

## 878 **Availability of data and materials**

879 The datasets generated and/or analysed during the current study are not publicly  
880 available due to the complexity of anonymisation, but are available from the  
881 corresponding author on reasonable request

882

## 883 **Competing interests**

884 The authors declare that they have no competing interests

885

## 886 **Funding**

887 This work was supported by the Medical Research Council Methodology Research

888 Programme (MRP) grant number MR/P026761/1

889

## 890 **Authors' contributions**

891 Claire Surr:

892 Conceptualization

893 Formal analysis

894 Funding acquisition

895 Investigation

896 Methodology

897 Writing – original draft

898

899 Laura Marsden:

900 Conceptualization

901 Data curation

902 Formal analysis

903 Investigation

904 Writing – original draft  
905  
906 Alys Griffiths:  
907 Data curation  
908 Writing – review & editing  
909  
910 Sharon Cox:  
911 Data curation  
912 Writing – review & editing  
913  
914 Jane Fossey:  
915 Data curation  
916 Writing – review & editing  
917  
918 Adam Martin:  
919 Data curation  
920 Writing – review & editing  
921  
922 A Toby Prevost:  
923 Data curation  
924 Writing – review & editing  
925  
926 Catherine Walshe:  
927 Data curation  
928 Writing – review & editing

929

930 Rebecca Walwyn:

931 Conceptualization

932 Data curation

933 Funding acquisition

934 Investigation

935 Methodology

936 Project administration

937 Supervision

938 Writing – original draft

## 939 **Acknowledgements**

940 We would like to thank the following people for their contributions to the expert

941 workshops: Professor Amanda Farrin, Professor Steph Taylor, Dr Clemence Leyrat,

942 Prof Sally Kerry, Dr David Meads, Professor Alan Montgomery, Prof Anne Forster,

943 Liz Graham.

944

945

## 946 **References**

947 1. Moberg J, Kramer M. A brief history of the cluster randomised trial design. J R

948 Soc Med. 2015;108(5):192-8.

949 2. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement:

950 extension to cluster randomised trials. BMJ : British Medical Journal.

951 2012;345:e5661.



- 952 3. Parker K, Nunns MP, Xiao Z, Ford T, Ukoumunne OC. Characteristics and  
953 practices of school-based cluster randomised controlled trials for improving health  
954 outcomes in pupils in the UK: a systematic review protocol. *BMJ Open*.  
955 2021;11(2):e044143.
- 956 4. Diaz-Ordaz K, Froud R, Sheehan B, Eldridge S. A systematic review of cluster  
957 randomised trials in residential facilities for older people suggests how to improve  
958 quality. *BMC Med Res Methodol*. 2013;13(1):127.
- 959 5. Dron L, Taljaard M, Cheung YB, Grais R, Ford N, Thorlund K, et al. The role  
960 and challenges of cluster randomised trials for global health. *The Lancet Global*  
961 *Health*. 2021;9(5):e701-e10.
- 962 6. Choko AT, Roshandel G, Conserve DF, Corbett EL, Fielding K, Hemming K,  
963 et al. Ethical issues in cluster randomized trials conducted in low- and middle-income  
964 countries: an analysis of two case studies. *Trials*. 2020;21(1):314.
- 965 7. Murray DM, Hannan PJ. Planning for the appropriate analysis in school-based  
966 drug-use prevention studies. *J Consult Clin Psychol*. 1990;58(4):458-68.
- 967 8. Chenoweth L, Forbes I, Fleming R, King MT, Stein-Parbury J, Luscombe G, et  
968 al. PerCEN: a cluster randomized controlled trial of person-centered residential care  
969 and environment for people with dementia. *Int Psychogeriatr*. 2014;26(7):1147-60.
- 970 9. Boorsma M, Frijters DH, Knol DL, Ribbe ME, Nijpels G, van Hout HP. Effects  
971 of multidisciplinary integrated care on quality of care in residential care facilities for  
972 elderly people: a cluster randomized trial. *CMAJ*. 2011;183(11):E724-32.
- 973 10. Williams KN, Perkhounkova Y, Herman R, Bossen A. A Communication  
974 Intervention to Reduce Resistiveness in Dementia Care: A Cluster Randomized  
975 Controlled Trial. *Gerontologist*. 2017;57(4):707-18.

- 976 11. Weintraub JA, Zimmerman S, Ward K, Wretman CJ, Sloane PD, Stearns SC,  
977 et al. Improving Nursing Home Residents' Oral Hygiene: Results of a Cluster  
978 Randomized Intervention Trial. *J Am Med Dir Assoc.* 2018;19(12):1086-91.
- 979 12. Slead M, Baradon T, Fonagy P. New Beginnings for mothers and babies in  
980 prison: a cluster randomized controlled trial. *Attach Hum Dev.* 2013;15(4):349-67.
- 981 13. O'Shea E, Devane D, Cooney A, Casey D, Jordan F, Hunter A, et al. The  
982 impact of reminiscence on the quality of life of residents with dementia in long-stay  
983 care. *Int J Geriatr Psychiatry.* 2014;29(10):1062-70.
- 984 14. Husebø BS, Ballard C, Aarsland D, Selbaek G, Slettebo DD, Gulla C, et al.  
985 The Effect of a Multicomponent Intervention on Quality of Life in Residents of  
986 Nursing Homes: A Randomized Controlled Trial (COSMOS). *J Am Med Dir Assoc.*  
987 2019;20(3):330-9.
- 988 15. Sambrook PN, Cameron ID, Chen JS, Cumming RG, Durvasula S, Herrmann  
989 M, et al. Does increased sunlight exposure work as a strategy to improve vitamin D  
990 status in the elderly: a cluster randomised controlled trial. *Osteoporos Int.*  
991 2012;23(2):615-24.
- 992 16. Vermandere M, Warmenhoven F, Van Severen E, De Lepeleire J, Aertgeerts  
993 B. Spiritual history taking in palliative home care: A cluster randomized controlled  
994 trial. *Palliat Med.* 2016;30(4):338-50.
- 995 17. Koczy P, Becker C, Rapp K, Klie T, Beische D, Büchele G, et al.  
996 Effectiveness of a multifactorial intervention to reduce physical restraints in nursing  
997 home residents. *J Am Geriatr Soc.* 2011;59(2):333-9.
- 998 18. Roos C, Silén M, Skytt B, Engström M. An intervention targeting fundamental  
999 values among caregivers at residential facilities: effects of a cluster-randomized

- 1000 controlled trial on residents' self-reported empowerment, person-centered climate  
1001 and life satisfaction. *BMC Geriatr.* 2016;16:130.
- 1002 19. Surr CA, Holloway I, Walwyn REA, Griffiths AW, Meads D, Kelley R, et al.  
1003 Dementia Care Mapping to reduce agitation in care home residents with dementia:  
1004 The DCM™ EPIC cluster randomised controlled trial. *Health Technol Assess.*  
1005 2020;24(16).
- 1006 20. Turner EL, Li F, Gallis JA, Prague M, Murray DM. Review of Recent  
1007 Methodological Developments in Group-Randomized Trials: Part 1—Design. *Am J*  
1008 *Public Health.* 2017;107(6):907-15.
- 1009 21. Group CR. Community Intervention Trial for Smoking Cessation (COMMIT):  
1010 Summary of Design and Intervention. *JNCI: Journal of the National Cancer Institute.*  
1011 1991;83(22):1620-8.
- 1012 22. Kasza J, Hooper R, Copas A, Forbes AB. Sample size and power calculations  
1013 for open cohort longitudinal cluster randomized trials. *Stat Med.* 2020;39(13):1871-  
1014 83.
- 1015 23. Ørngreen R, Levinsen K. Workshops as a research methodology. *The*  
1016 *Electronic Journal of e-learning.* 2017;15(1):70-81.
- 1017 24. Gustafsson T, editor *Expert Consultation in the Preparation of a National*  
1018 *Technology Programme 2004.*
- 1019 25. Surr CA, Holloway I, Walwyn REA, Griffiths AW, Meads D, Martin A, et al.  
1020 Effectiveness of Dementia Care Mapping™ to reduce agitation in care home  
1021 residents with dementia: an open-cohort cluster randomised controlled trial. *Aging &*  
1022 *Mental Health.* 2021;25(8):1410-23.

- 1023 26. Clarke V, Braun V, Hayfield N. Thematic Analysis. In: Smith JA, editor.  
1024 Qualitative Psychology: A Practical Guide to Research Methods. London: Sage;  
1025 2015.
- 1026 27. Jordhøy MS, Kaasa S, Fayers P, Underland G, Ahlner-Elmqvist M.  
1027 Challenges in palliative care research; recruitment, attrition and compliance:  
1028 experience from a randomized controlled trial. *Palliat Med*. 1999;13(4):299-310.
- 1029 28. Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, et al.  
1030 Allocation techniques for balance at baseline in cluster randomized trials: a  
1031 methodological review. *Trials*. 2012;13(1):120.
- 1032 29. Caille A, Kerry S, Tavernier E, Leyrat C, Eldridge S, Giraudeau B. Timeline  
1033 cluster: a graphical tool to identify risk of bias in cluster randomised trials. *BMJ*.  
1034 2016;354:i4291.
- 1035 30. Farrin A, Russell I, Torgerson D, Underwood M. Differential recruitment in a  
1036 cluster randomized trial in primary care: the experience of the UK Back pain,  
1037 Exercise, Active management and Manipulation (UK BEAM) feasibility study. *Clinical*  
1038 *Trials*. 2005;2(2):119-24.
- 1039 31. Easter C, Thompson JA, Eldridge S, Taljaard M, Hemming K. Cluster  
1040 randomized trials of individual-level interventions were at high risk of bias. *J Clin*  
1041 *Epidemiol*. 2021;138:49-59.
- 1042 32. Bolzern JE, Mitchell A, Torgerson DJ. Baseline testing in cluster randomised  
1043 controlled trials: should this be done? *BMC Med Res Methodol*. 2019;19(1):106.
- 1044 33. Eldridge S, Kerry S, Torgerson DJ. Bias in identifying and recruiting  
1045 participants in cluster randomised trials: what can be done? *BMJ*. 2009;339:b4006.

- 1046 34. Musa MK, Akdur G, Brand S, Killett A, Spilsbury K, Peryer G, et al. The  
1047 uptake and use of a minimum data set (MDS) for older people living and dying in  
1048 care homes: a realist review. *BMC Geriatr.* 2022;22(1):33.
- 1049 35. Clarke GM, Conti S, Wolters AT, Steventon A. Evaluating the impact of  
1050 healthcare interventions using routine data. *BMJ.* 2019;365:l2239.
- 1051 36. Lewsey J, Leyland A, Murray G, Boddy A. Using routine data to complement  
1052 and enhance the results of randomised controlled trials. *Health Technol Assess.*  
1053 2000;4.
- 1054 37. Todd OM, Burton JK, Dodds RM, Hollinghurst J, Lyons RA, Quinn TJ, et al.  
1055 New Horizons in the use of routine data for ageing research. *Age Ageing.*  
1056 2020;49(5):716-22.
- 1057 38. Burton JK, Wolters AT, Towers A-M, Jones L, Meyer J, Gordon AL, et al.  
1058 Developing a minimum data set for older adult care homes in the UK: exploring the  
1059 concept and defining early core principles. *The Lancet Healthy Longevity.*  
1060 2022;3(3):e186-e93.
- 1061 39. Health Data Research UK and NIHR Applied Research Collaboration (ARC)  
1062 West. Applied social care research using routine data: potential and challenges  
1063 HDRUK; 2020.
- 1064 40. Burton JK, Goodman C, Guthrie B, Gordon AL, Hanratty B, Quinn TJ. Closing  
1065 the UK care home data gap - methodological challenges and solutions. *International*  
1066 *Journal of Population Data Science.* 2020;5(4).
- 1067 41. Clegg A, Bandeen-Roche K, Farrin A, Forster A, Gill TM, Gladman J, et al.  
1068 New horizons in evidence-based care for older people: individual participant data  
1069 meta-analysis. *Age Ageing.* 2022;51(4).

- 1070 42. Meads DM, Martin A, Griffiths A, Kelley R, Creese B, Robinson L, et al. Cost-  
1071 Effectiveness of Dementia Care Mapping in Care-Home Settings: Evaluation of a  
1072 Randomised Controlled Trial. *Applied Health Economics and Health Policy*. 2019.
- 1073 43. Hooper R. Key concepts in clinical epidemiology: Stepped wedge trials. *J Clin*  
1074 *Epidemiol*. 2021;137:159-62.
- 1075 44. Li J, Zhang Y, Myers LJ, Bravata DM. Power calculation in stepped-wedge  
1076 cluster randomized trial with reduced intervention sustainability effect. *J Biopharm*  
1077 *Stat*. 2019;29(4):663-74.
- 1078 45. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al.  
1079 Better reporting of interventions: template for intervention description and replication  
1080 (TIDieR) checklist and guide. *BMJ*. 2014;348:g1687.
- 1081 46. Rowbotham S, Conte K, Hawe P. Variation in the operationalisation of dose in  
1082 implementation of health promotion interventions: insights and recommendations  
1083 from a scoping review. *Implementation Science*. 2019;14(1):56.
- 1084